Analyst Price Targets — EYPT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 20, 2026 9:50 am | Lisa Walter | RBC Capital | $1.00 | $0.44 | StreetInsider | EyePoint Inc. (EYPT) PT Lowered to $1 at RBC Capital |
| October 20, 2026 9:31 am | Graig Suvannavejh | Mizuho Securities | $0.50 | $0.44 | StreetInsider | Mizuho Downgrades EyePoint Inc. (EYPT) to Neutral 'on Negative P3 Data, Lack of Catalysts, Financing Overhang' |
| October 19, 2026 2:02 pm | Faisal Khurshid | Jefferies | $1.00 | $0.42 | TheFly | EyePoint downgraded to Hold from Buy at Jefferies |
| September 2, 2026 6:04 am | — | China Renaissance Securities (US) Inc. | $4.00 | $4.58 | StreetInsider | TD Cowen Downgrades EyePoint Inc. (EYPT) to Hold |
| August 18, 2026 12:01 pm | — | Chardan Capital | $5.00 | $5.31 | TheFly | EyePoint downgraded to Neutral from Buy at Chardan |
| August 18, 2026 12:51 am | — | RBC Capital | $5.00 | $4.87 | TheFly | EyePoint downgraded to Sector Perform from Outperform at RBC Capital |
| August 17, 2026 4:35 pm | — | Jefferies | $8.00 | $4.61 | TheFly | EyePoint price target lowered to $8 from $30 at Jefferies |
| August 6, 2026 10:17 am | — | H.C. Wainwright | $27.00 | $12.25 | TheFly | EyePoint price target lowered to $27 from $30 at H.C. Wainwright |
| July 29, 2026 10:53 am | Graig Suvannavejh | Mizuho Securities | $39.00 | $11.96 | StreetInsider | EyePoint Inc. (EYPT) PT Raised to $39 at Mizuho, 'Top Pick' |
| July 15, 2026 8:12 pm | Annabel Samimy | Stifel Nicolaus | $40.00 | $13.85 | TheFly | EyePoint initiated with a Buy at Stifel |
Latest News for EYPT
What happened EyePoint, Inc. (NASDAQ: EYPT) said on October 19, 2026 that it is shifting its focus to DURAVYU for diabetic macular edema after LUCIA missed its primary endpoint. The board approved a plan to cut the workforce by about 53% and end the pivotal Phase 3 wet AMD trials early, before the second year
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint PharmaceuticalsPR NewswireNEW YORK, Oct. 20, 2026
EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU patients.
EyePoint Pharmaceuticals shares lost nearly 80% of their value following the disappointing Phase 3 LUCIA trial results for DURAVYU in wet age-related macular degeneration. Levi & Korsinsky is investigating potential securities law violations on behalf of EYPT shareholders who lost money.
EyePoint Inc. (NASDAQ:EYPT) is slashing its workforce by 53% and halting wet age-related macular degeneration clinical trials early following disappointing Phase 3 results.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for EYPT.
U.S. House Trading
No House trades found for EYPT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.